Gilead Sciences, Inc. (GILD) Speculators Eye the $100 Mark

Gilead Sciences, Inc. (GILD) call buyers anticipate an extended run into triple-digit territory

Digital Content Group
Feb 11, 2015 at 11:26 AM
facebook X logo linkedin


Gilead Sciences, Inc. (NASDAQ:GILD) is up 2.1% this morning to trade at $100.43, following encouraging comments surrounding the firm's hepatitis C drug, Sovaldi. As such, call volume has ramped up to 1.4 times the expected intraday pace.

GILD's most active option is the February 100 call, which appears to be seeing some buy-to-open activity. In short, these traders expect the stock to extend its run north of the round-number century mark through next Friday's close, when the front-month contracts expire. The shares haven't closed above $100 since Feb. 3, prior to a guidance-induced bear gap. However, with today's rally, delta on the at-the-money option has jumped to 0.55 from 0.36 at Tuesday's close, signaling an increased probability of an in-the-money finish.

As alluded to, GILD is running higher on positivity surrounding Sovaldi, as the company said it expects usage throughout Europe to increase dramatically this year -- and also expressed optimism that approvals for its combination pill, Harvoni, could be forthcoming. Elsewhere, WellCare Health Plans, Inc. (NYSE:WCG) has reaffirmed its alignment with GILD as its "clinical choice" for hepatitis C treatment.

Technically speaking, Gilead Sciences, Inc. (NASDAQ:GILD) has had a nice run over the previous 12 months. On a year-over-year basis, the shares have advanced 22.5%. However, after bouncing from their 200-day moving average, they're currently testing resistance in the $100 area, which corresponds with last week's downside gap and served as support on several occasions in the latter half of 2014.

Daily Chart of GILD since August 2014 with 200-Day Moving Average

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI